Difference between revisions of "Fulvestrant (Faslodex)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
||
| Line 32: | Line 32: | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
| − | [[Category: | + | [[Category:FDA approved in 2002]] |
Revision as of 19:03, 30 July 2018
General information
Class/mechanism: Estrogen receptor antagonist; competitively binds to the estrogen receptor (ER) and downregulates estrogen receptor expression.[1][2][3]
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Fulvestrant (Faslodex) package insert[1]
- Fulvestrant (Faslodex) patient drug information (Chemocare)[4]
- Fulvestrant (Faslodex) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 4/25/2002: Initial FDA approval for "the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Also known as
- Brand names: Faslodex, Fasnorm, Fulvenat, Fulvidax, Fuvestrol